Healthcare Belgian Community
Our community narratives are driven by numbers and valuation.
Healthcare Belgian Investing Ideas
Agfa-Gevaert is a digital and materials turnaround opportunity, with growth potential in ZIRFON, but carrying legacy risks.
Agfa-Gevaert is trying to turn itself from a fading film business into a focused company built around hospital imaging software, industrial printers, and new materials used in clean-energy equipment. The upside comes from newer products gaining traction, but the company still has to manage old liabilities and the slow decline of its legacy film activities.Read more
Regulatory Delays Will Hinder Revenue Ramp But Allow Recovery
Nyxoah’s sleep apnea implant looks well timed as more people get diagnosed and demand grows for alternatives to bulky machines, but the U.S. rollout may move slower than many expect. Regulatory reviews, insurance coverage decisions, and intensifying competition could keep losses high and squeeze pricing before the business has a chance to scale.Read more
Minimally Invasive Devices Will Capture Expanding Sleep Market
A small medical device company is betting that its Genio implant can make sleep apnea treatment easier for more patients, helping it win over busy U.S. clinics as diagnosis rates rise. The upside is tied to smooth approvals and insurance coverage, but a single-product business and ongoing legal and competitive pressure could quickly derail the story.Read more
FDA Approval And Expanding Network Will Grow US Sleep Market
Nyxoah has fresh U.S. approval for its Genio implant and is building a fast-growing network of doctors and sleep centers that could help more people move beyond CPAP therapy. But bigger rivals are pushing back, and legal fights, reimbursement delays, and heavy spending could slow the rollout before the business can stand on its own.Read more
Clinic And Home Neuromodulation Adoption Will Drive Long Term Opportunity
Onward Medical is betting that more rehab clinics adopt its ARC-EX therapy and that patients eventually use it at home, turning early interest into steadier, repeat use. The upside depends on insurance coverage and trial results for a second use case, while cash burn and changing healthcare rules could slow the rollout.Read more
APAC Expansion And Compounding Services Will Unlock Future Value
Fagron is pushing into new regions and leaning into made-to-order medicines as hospitals and pharmacies look for more flexible options amid drug shortages and an aging population. The big question is whether its growth plan and upgrades in automation can outweigh supply chain, regulatory, and currency bumps along the way.Read more
Neurostimulation Adoption And Brain Computer Interfaces Will Transform Long Term Prospects
Catalysts About Onward Medical Onward Medical develops neurostimulation therapies aimed at improving function and quality of life for people with spinal cord injury and related movement disabilities. What are the underlying business or industry changes driving this perspective?Read more
Challenged Reimbursement And Cash Burn Will Test Neurostimulation Thesis Yet Long Term Potential Remains
Catalysts About Onward Medical Onward Medical develops and commercializes neurostimulation systems intended to improve function and quality of life for people with spinal cord injury. What are the underlying business or industry changes driving this perspective?Read more
Proton Therapy Expansion Will Transform Global Cancer Treatment
Key Takeaways Sustained demand for advanced proton therapy and expansion into new markets are driving long-term revenue growth and improved earnings visibility. Continued R&D investments and growth in service contracts are enhancing margins, competitive positioning, and recurring high-margin revenue streams.Read more
